Clinical Trials · NCT02014259
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 71
- Start date
- Dec 2013
- Locations
- 4 sites, Czechia, Hungary
- Primary endpoint
- Area under the semaglutide plasma concentration time curve